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dence surveillance process was established based on a systematic search of PubMed, 
using key words relevant to economic modelling in healthcare or disease and lim-
ited to studies published in English, in humans, and with abstracts. The surveillance 
incorporated all studies published from 2010 and was updated weekly. Abstracts 
identified by the search of economic evaluation studies were indexed according to 
disease area, using the chapter categorisation from ICD-10 as a framework. Articles 
were also included if they analysed the cost-effectiveness of healthcare service design 
or explored methodological issues related to economic modelling. To account for the 
delay in indexing of publications, we included all studies with a publication date of 
2014 that were indexed in PubMed up to 8 June 2015. Results: The search identified 
2,772 articles published in 2014. Of these, 836 met the inclusion criteria and were sub-
categorised according to topic. The greatest number, 19%, were conducted in patients 
with infectious diseases, with 14% in cancer, 12% in cardiovascular disease, 8% in mus-
culoskeletal disorders, 7% in mental health disorders, 6% in endocrine or metabolic 
disorders and 4% in digestive disorders. A further 7% of identified papers reported 
on modelling methods and 3% on service design. All other disease areas accounted 
for 3% or fewer of the relevant publications per ICD-10 chapter. ConClusions: The 
focus of economic evaluations in 2014 was on infectious diseases, followed by cancer 
and cardiovascular disease. As these three disease areas accounted for almost 60% 
of global mortality in 2012, and cause considerable morbidity, it is encouraging to see 
that health economic research has prioritised finding the most cost-effective ways 
to reduce this burden.
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objeCtives: Since October 2013 HAS is required to provide the inter-ministerial 
pricing committee (CEPS) with an economic evaluation on innovative drugs and 
medical devices likely to have a significant impact on national health insurance 
expenditure. HAS’ evaluation involves a critical appraisal of cost-effectiveness 
analyses (CEA) submitted by manufacturers. Although budget impact analysis 
(BIA) is currently not required by HAS, it may be provided as an optional com-
plement to CEA. Our objective was to assess how BIA was undertaken in manu-
facturers’ submissions. Methods: We used a qualitative approach to assess 
manufacturers’ submissions by end of April 2015 (n= 49). As currently there is 
no formal HAS guideline on BIA, we used the recommendations of the French 
Collège des économistes de la santé as well as ISPOR Task Force Principles on Good 
Practices for BIA as an analytical framework, including perspective, time horizon, 
discounting, size of eligible populations, current comparators, anticipated uptake 
of the new technology, and cost of treatments. Results: Eleven (22%) submissions 
included a BIA along with the CEA. Compliance with ISPOR Task Force principles 
was generally fair for perspective, time horizon and discounting. The selection of 
current comparators was considered problematic in 7 (64%) of these submissions. 
Regarding costs of treatments, the majority of BIA failed to include adverse events 
as well as follow-up costs. In most cases, there was a lack of transparency on BIA 
modelling and eligible population size estimates. Furthermore, in 9 (80%) BIA, sce-
narios were not explored through adequate sensitivity analyses. ConClusions: 
Although based on a small number of submissions, our study identified concerns 
about population size estimates, comparators, identification of costs beyond treat-
ment acquisition and administration, BIA interpretation and scenarios sensitivity 
analyses. This raises the need to include explicit recommendations on BIA in the 
next, updated version of the HAS guideline on economic evaluation.
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objeCtives: In our study we investigated how monetary payment of sick-pay from 
National Health Insurance Fund Administration changed in the analysed period 
according to groups of illnesses. Methods: We used the data of National Health 
Insurance Fund Administration of Hungary and statistical reports of Nr. OSAP 1514, 
as well as data of Hungarian Central Statistical Office from the period between 2005-
2013. At the determination of groups of illnesses we used the main diagnosis of ICD 
classification of diseases. We analysed the following indicators: the number or sick-
pay cases as well as the number of days spent on sick leave with regards to groups 
of illnesses. Results: After having analysed the data we can ascertain that mostly 
musculoskeletal illnesses can be named as reasons for adhering to sick-pay every 
year. (24-28% of all cases) The average time spent on sick-leave in these cases was 
33-41 days. The inflammatory disease of the respiratory system was the second cause 
every year (17-20% of all cases). Resorting to sick-pay because of mental illnesses fell 
from 9 to 5%. The period of sick-leave continuously decreased from 2009. The short-
est, on average 7-18 days of sick-pay was resorted to because of infectious diseases; 
due to the infectious disease of the respiratory system people were on sick-leave for 
12-19 days on average. The period spent on sick-leave because of cancer diseases in 
the investigated years was 55-65 days. ConClusions: Significant decrease occurred 
in the case of days spent on sick-leave due to mental and nervous system diseases 
(2007: 50 days, 3013: 33 days) and inflammatory disease of the respiratory system 
(2005: 19 days, 2013: 12 days).
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objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when 
wholesalers were also authorized, pharmaceuticals under this status could only 
be imported by the Turkish Pharmacists’ Association (TPA The aim of this study is to 
understand the trends in L group (Antineoplastic and immunomodulating agents) 
of ATC classification system unlicensed medicine consumption between 2011 and 
2013 when the TPA was the only authorized supplier. Methods: Consumption 
data of L group in the top 100 imported unlicensed medicines with the highest 
sales share in total expenses of imported off-label use was taken from the TMMDA 
computer database. Descriptive analysis was conducted. Results: The analysis 
showed that the numbers of active ingredients of L group in the top 100 rose from 
37 to 55, between 2011 and 2013. The average cost per box of unlicensed medicines 
in the L group increased from 4.973 TL to 7.436 TL in the same period. The total 
consumption of the unlicensed medicines in L group increased from 107 billion TL 
to 482 billion TL. ConClusions: The cost of imported unlicensed medicines used 
increased every year in Turkey. Some cost-containment measures (especially for 
antineoplastic medicines) should be taken to reduce the increasing cost without 
risking the patients’ access to these innovative medicines.
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objeCtives: The objective of this study was to analyze the costs of septic shock in 
2012 for England, Wales and Northern Ireland. Methods: We analyzed length of stay 
and organ support of 20,549 adult septic shock patients. Septic shock was defined 
as severe sepsis including the presence of cardiovascular organ dysfunction. Data 
derived from the Case Mix Programme Database. This is the national, comparative 
audit of patient outcomes from adult critical care coordinated by the Intensive Care 
National Audit & Research Centre (ICNARC). These analyses were based on data from 
136,880 admissions to 205 adult, general critical care units (CCU) based in NHS hos-
pitals geographically spread across England, Wales and Northern Ireland. Unit costs 
were obtained from the National Schedule of Reference Costs 2012-2013. Results: 
There were 22,081 admissions to CCU, with an average duration of 7.6 days. At a cost 
per day of £1044, this adds up to £175.2 million. There were 14,471 admissions to a 
post-unit discharge location (23.3 days, £240/day). Total ward cost is thus about £80.9 
million. Renal and advanced respiratory support was required by 4,440 and 13,797 
individuals, respectively (both cost £285/day). With an average duration of 5.4 days for 
renal and 7.7 days for respiratory support, the total costs amount to £6.8 million and 
£30.3 million, respectively. Therefore, the total cost of septic shock is estimated to be 
around £293.2 million. ConClusions: With annual costs of nearly £300 million, it 
is evident that septic shock patients pose a heavy burden to the national healthcare 
system. These patients require lengthy hospital stays, as well as substantial renal 
and respiratory support. Adding drug costs, societal costs, as well as Scottish data, 
would increase the total costs even further. Septic shock is a costly disease and every 
effort should be made to reduce this burden to the patients, hospitals and society.
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objeCtives: The role of ‘disinvestment’ in health care, i.e., the withdrawal (partially 
or completely) of interventions that provide no or marginal benefit compared to 
alternative therapeutic approaches is attracting worldwide attention. The objective of 
this study was to identify and review empirical evaluations of disinvestment programs 
to gauge their success and determine key challenges. Methods: We systematically 
searched the medical literature using the PubMed database for empirical evalua-
tions of disinvestment programs using the following search terms; “disinvestment”, 
“resource allocation”, “low value”, and “priority setting”. We did not restrict our search 
in regards to study publication year. Two researchers assessed each identified abstract. 
For each study, we reported the disinvestment program that was assessed and cat-
egorized study findings as ‘successful’ if a reduction in utilization of the low-value 
service was reported, and ‘unsuccessful’ if no reduction in utilization was reported. 
We also reported challenges identified by the study authors in the implementation of 
the disinvestment program. Results: We identified 34 studies describing empirical 
evaluations of disinvestment programs. Fifteen pertained to the National Institute 
for Health and Care Excellence’s recommendations, and/or their ‘do not do list,’ 8 per-
tained to the Choosing Wisely Campaign, and 11 pertained to unique initiatives world-
wide—including the French initiative to delist unnecessary pharmaceuticals with the 
help of its Transparency Commission. The empirical evaluations varied with respect 
to the reported success of the disinvestment programs: twenty-one determined the 
program to be successful, and 13 unsuccessful. Common challenges reported by study 
authors include difficulty in identifying low-value care for disinvestment and gaining 
support among stakeholders. ConClusions: Empirical evaluation of disinvestment 
programs is limited. Available evaluations report varied success for existing disinvest-
ment strategies and noted that a number of key challenges are yet to be overcome.
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objeCtives: To determine the disease focus of all economic evaluation papers 
indexed in the PubMed database that were published in 2014. Methods: An evi-
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RU (10%). Similar impacts were observed for ES. Based on the real life dataset, a 10% 
decrease DE would lead to a range of reductions across Europe including 16% in 
Denmark, 12% in Austria, 10% in HR and 5% in Netherlands. ConClusions: Price 
reductions of branded therapies in any of the key European markets would likely 
have a significant impact on prices in other markets reducing overall profits for the 
pharmaceutical industry.
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objeCtives: As the result of the 2007 economic crisis, the number of employed 
significantly decreased. In our study we investigated how the number of people 
entitled for sick-pay, the number of days resorting to sick-pay and the number 
of sick-leave days in ratio with one sick-pay case changed in this period regard-
ing age groups and genders. Methods: We used the data of the National Health 
Insurance Fund Administration of Hungary, statistical reports of Nr. OSAP 1514, as 
well as data of Hungarian Central Statistical Office from the period from the years 
between 2005 and 2013. We analysed the number of employees entitled for sick-pay, 
the number of days spent on sick-leave. Results: In the period under investiga-
tion the number of employees entitled for sick-pay increased from 3.486 to 3.796 
thousand people, however, at the same time, the number of sick-pay cases fell 
from 1,252.000 to 825.000, and the number of days spent on sick-leave generally fell 
from 30 to 24. Women spent generally 40-56 percent more days on sick-leave which 
mostly came from childcare. Between the years of 2007 and 2009, people adhering to 
sick-pay were mostly between the ages of 30-34 (28-21%), while from 2010 between 
the ages of 35-39 (20%). This is connected to the number of people employed. From 
2009, the number of employees significantly increase in the age group 55-59 (2008: 
46,2%, 2013:58,4%), and simultaneously the number of people adhering to sick-pay 
also became higher. ConClusions: Based on the comprehensive analysis of the 
statistical data we can ascertain that adhering to sick-pay is in close connection 
with the employment ratio. Furthermore, we can say that in the period after the 
2008 economic crisis the number of days spent on sick-leave fell with 35% and the 
number of days on sick-leave fell with 20%.
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objeCtives: This paper examines the short- and long-run effect of biosimilar entry 
on price erosion. Furthermore, the impact of increases in the number of competi-
tors on prices of originators is investigated. Methods: A series of explanatory 
analyses have been performed using an econometric model which was developed 
for the years 2008–2014 spanning across 10 European countries: Bulgaria, France, 
Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, and the UK. Two 
successful biosimilars were considered for the analyses: filgrastim and epoetins. A 
semi-structured literature review as well as a survey and interviews with country 
experts have been conducted to understand price dynamics in each market. Prices 
were obtained from country experts and verified with IMS Health. The model used 
dynamic panel data analysis, utilising Ordinary Least Squares regression with fixed 
effects, subjected to a Granger causality test. Results: The study assumes that the 
prices of currently marketed biosimilars define the attractiveness of the market and 
impact the entry decision of further competitors. This assumption was confirmed 
for epoetins, where each next biosimilar entrant in the current month leads to a 
7% (p= 0,0001) price decrease next month, with a long-run sustained effect of 4% 
(p= 0,1806). The entrance of new competitors has the highest impact on price erosion 
in Bulgaria, Italy and Poland. There is a strong trend indicating that a doubling in 
the number of competitors leads to about 10% (p= 0,1266) decrease in the originator 
prices in the long-run for filgrastim, with strongest effect in Bulgaria. This effect is 
insignificant for epoetins (p= 0,9694). ConClusions: Biosimilars manufacturers 
should carefully analyse the number of competitors planning to enter the mar-
ket when making strategic decisions on the investment in the development of 
biosimilars.
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france In tHe age Of OPen data
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objeCtives: In the interest of increasing transparency and access to healthcare 
utilization data, the French government has published the highly anticipated Open 
DAMIR database (Dépenses Assurance Maladie Inter-Régimes). The objective of this 
study was to perform an exploratory analysis of the DAMIR database in order to 
estimate the mean cost of each type of physician visit and the mean surcharge rate 
for technical procedures, by specialty, in order to better inform health economic mod-
eling in the French setting. Methods: The DAMIR database consists of monthly 
extractions of data from the larger French national health insurance limited-access 
database. We analyzed data collected over a 3-month period (September-November 
2014), comprising a total of 98,684,544 outpatient visits and 54,310,532 technical pro-
cedures (including outpatient and inpatient procedures, Diagnosis-Related Group 
billing excepted). Total costs were estimated from the all-payer perspective, in 
accordance with French guidelines. We calculated mean costs for each type of visit, 
including surcharges, and the mean surcharge rate for technical procedures for each 
specialty. Results: The three types of visits associated with the highest mean costs 
were for neurologists (€ 50.58 per visit), surgeons (€ 45.74), and psychiatrists (€ 43.96), 
whereas the lowest mean costs were for general practitioners (€ 24.12), nephrologists 
(€ 25,58), and geriatricians (€ 29.58). The highest surcharge rates for technical proce-
dures were billed by surgeons (mean surcharge of +55.6% of the minimum reimburs-
1Amaris, London, UK, 2General Agency of Equipment and Health Products (AGEPS),Assistance 
Publique-Hôpitaux de Paris (AP-HP); Faculty of Pharmacy, Paris Descartes University, Sorbonne 
Paris Cité; Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Paris, France, 
3Université Paris-Dauphine, Paris, France
objeCtives: To compare technology-specific cost-effectiveness analyses (CEA) 
submitted as part of health technology assessments (HTA) in France, England 
and Canada and to highlight the comments, criticisms and conclusions from the 
HTA agencies in order to assess the feasibility of a unified approach. Methods: 
Newly published health economic appraisals from the French National Authority 
for Health (HAS) were reviewed, analyzed and compared to technology apprais-
als and/or evidence review group (ERG) reports in other countries for the same 
drugs including sofosbuvir (Sovaldi®), trastuzumab emtansine (Kadcyla®), riociguat 
(Adempas®) and dolutegravir (Tivicay®). The analysis focused first on the review 
of methodological approach selected by the manufacturer including model type, 
time horizon, discount rates, perspective, study population, comparators as well as 
efficacy, costs and utility data and presentation of results (i.e. total costs and health 
benefit, incremental cost-effectiveness ratio from both base-case and sensitivity 
analyses). The analysis then focused on comments made by the agency committees, 
criticisms and overall conclusions. For each drug, a comparison between models 
used and agencies’ final recommendations was undertaken to highlight convergent 
and divergent points between countries. Results: Results were heterogeneous 
between drugs which made it difficult to draw a general overarching conclusion. 
Nevertheless, some points were underlined by every agency. As an example, French, 
English and Canadian HTA agencies all drew attention to small patient samples and 
their impacts on the robustness of efficacy data for subgroups in several assess-
ments, which led to uncertainty around estimates of clinical effectiveness and 
therefore cost-effectiveness. ConClusions: Cost-effectiveness analyses have been 
introduced in France as part of the assessment of new health technologies two years 
ago whereas it has been used for about 15 and 20 years in England and Canada 
respectively. This review highlighted the level of similarities between countries 
to assess the feasibility of a unified approach to prepare the submission process.
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objeCtives: Hospital pharmaceutical expenditure dropped by almost 50% after 
memorandum measures were first in place. Severe cuts imposed on targets of phar-
maceutical expenditure between 2012 and 2014, run parallel to a variety of general 
reform measures, affecting primary care and non-hospital access to pharmaceuti-
cals. The aim of this study was to isolate main achievements versus other hospital 
cost-drivers. Methods: End-year 2012-2014 invoiced data from all hospitals in 
Greece were analysed, in order to examine trends in pharmaceutical versus non-
pharmaceutical savings. Non-pharmaceutical savings included costs on appliances, 
orthopaedics and diagnostics. A separate analysis looked at total pharmaceutical 
expenditure versus costs of outsourcing services and other expendables such as 
medical gas and energy supplies. Total expenditure for pharmaceuticals was then 
compared to volumes in unit boxes for the respective years, in order to examine 
effectiveness of other reform measures, other than price erosion and discounts/
rebates offered such as electronic and INN prescribing. Results: Hospital pharma-
ceutical expenditure dropped by 31% over three years, from € 761M in 2012, to € 642M 
in 2013 and € 519M in 2014, when respective savings for orthopaedics, healthcare 
appliances and diagnostics amounting to 6%, 25% and 13% respectively (cumulative 
2014 was € 508M). Total savings due to outsourcing services and medical and energy 
supplies reached (-)26% and (-)20% respectively, with an absolute sum of € 180M over 
the three years. Regarding volumes of hospital lines for the three respective years, 
unit numbers dropped from 84,525,999, to 79,987,535 and 77,075,298 unit-boxes. 
When calculating pharmaceutical costs, hospitals spent on average € 9.00, € 8.02 and 
€ 6.74 per unit used in 2012, 2013 and 2014 respectively. ConClusions: Significant 
savings have been achieved for pharmaceuticals in the Greek hospital setting. The 
cuts were mainly attributable to improved cost/pack ratio, but a notable decrease in 
units was also observed. Percentage savings in pharmaceuticals were higher than 
respective savings achieved in other hospital cost-drivers.
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objeCtives: International Reference Pricing (IRP) is a key cost-containment method 
for health care payers. We have developed based on local experts and publically 
available IRP rules a user-friendly price management tool (Orange) designed 
to enable the real-time forecasting of the global pricing impact of a branded 
launched product price change in a single market. The objective of this analysis is 
to explore, using Orange, the potential impact of price reductions in key EU mar-
kets. Methods: Two price datasets were used to illustrate core features of the 
Orange tool. In the first all prices were set at € 10 and in the second (real life dataset) 
prices were in the range of € 1.78-2.86 (highest for UK followed by DE, ES, IT and FR). 
With each dataset prices were varied for Germany (DE), UK, France (FR), Spain (ES) 
and Italy (IT). Results: A DE price decrease would result in the greatest number of 
reductions elsewhere. A 10% decrease in DE (on € 10) would lead to the same % reduc-
tion in FR, Romania (RO), Russia (RU), Slovenia (SI), Croatia (HR) and Luxembourg (LU) 
and smaller reductions in multiple other countries. A 10% reduction in UK would 
lead mainly to a 10% decrease in FR, RO and HR. A 10% price reduction in FR would 
have greatest impact in HR (13%), SI and RU (10%) and in IT it would be FR, RO and 
